Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2019

Open Access 01-12-2019 | Tuberculosis | Research article

Survival analysis of time to cure on multi-drug resistance tuberculosis patients in Amhara region, Ethiopia

Authors: Yigzaw Alemu Limenih, Demeke Lakew Workie

Published in: BMC Public Health | Issue 1/2019

Login to get access

Abstract

Background

Multidrug-resistant tuberculosis (MDR-TB) is caused by bacteria that are resistant to the most effective anti-tuberculosis drug. The MDR-TB is an increasing global problem and the spread of MDR-TB has different recovery time for different patients. Therefore, this study aimed to investigate the recovery time of MDR-TB patients in Amhara region, Ethiopia.

Method

A retrospective study was carried out in seven hospitals having MDR-TB treatment center of Amhara region, Ethiopia from September 2015 to February 2018. An accelerated failure time and parametric shared frailty models were employed.

Results

The study revealed that the recovery time of MDR-TB patients in Amhara region was 21 months. Out of the total MDR-TB patients, 110 (35.4%) censored and 201 (64.6%) cured of MDR-TB. The clustering effect of frailty model was hospitals and the Weibull-gamma shared frailty model was selected among all and hence used for this study. The study showed that extra pulmonary MDR-TB patients had longer recovery time than that of seamier pulmonary MDR-TB patients in Amhara region, Ethiopia. According to this study, male MDR-TB patients, MDR-TB patients with co-morbidity and clinical complication were experiencing longer recovery time than that of the counter groups. This study also showed that MDR-TB patients with poor adherence had longer recovery time than those with good adherence MDR-TB patients.

Conclusion

Among different factors considered in this study, MDR-TB type, clinical complication, adherence, co-morbidities, sex, and smoking status had a significant effect on recovery time of MDR-TB patients in Amhara region, Ethiopia.
In conclusion, the Regional and Federal Government of Ethiopia should take immediate steps to address causes of recovery time of MDR-TB patients in Amhara region through encouraging adherence, early case detection, and proper handling of drug-susceptibility according to WHO guidelines.
Literature
1.
WHO. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NCSA 3.0 IGO
2.
WHO: Multidrug and extensively drug-resistant TB. (M/XDR-TB) 2010 Global Report On Surveillance And Response 2010.
3.
Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61(2):158–63.CrossRef
4.
Kundu D, Sharma N, Chadha S, Laokri S, Awungafac G, Jiang L, Asaria M. Analysis of multi drug resistant tuberculosis (MDR-TB) financial protection policy: MDR-TB health insurance schemes, in Chhattisgarh state, India. Health Econ Rev. 2018;8(1):3.CrossRef
5.
Singh JA, Upshur R, Padayatchi N. XDR-TB in South Africa: no time for denial or complacency. PLoS Med. 2007;4(1):e50.CrossRef
6.
Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature. 2011;469(7331):483.CrossRef
7.
Assefa D, Seyoum B, Oljira L. Determinants of multidrug-resistant tuberculosis in Addis Ababa, Ethiopia. Infect Drug Resist. 2017;10:209.CrossRef
8.
Eldholm V, Balloux F. Antimicrobial resistance in mycobacterium tuberculosis: the odd one out. Trends Microbiol. 2016;24(8):637–48.CrossRef
9.
Getachew T, Bayray A, Weldearegay B. Survival and predictors of mortality among patients under multi-drug resistant tuberculosis treatment in ethiopia: st. Peter's specialized tuberculosis hospital, ethiopia. Int J Pharm Sci Res. 2013;4(2):776.
10.
Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, Weyer K. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3):1602308.CrossRef
11.
Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C. Global trends in resistance to antituberculosis drugs. N Engl J Med. 2001;344(17):1294–303.CrossRef
12.
Tyrrell F, Stafford C, Yakrus M, Youngblood M, Hill A, Johnston S. Trends in testing for mycobacterium tuberculosis complex from US public health laboratories, 2009–2013. Public Health Rep. 2017;132(1):56–64.CrossRef
13.
Tacconelli E, Cataldo M, Dancer S, De Angelis G, Falcone M, Frank U, Kahlmeter G, Pan A, Petrosillo N, Rodríguez-Baño J. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20:1–55.CrossRef
14.
Alrabiah K, Al Alola S, Al Banyan E, Al Shaalan M, Al Johani S. Characteristics and risk factors of hospital acquired–methicillin-resistant Staphylococcus aureus (HA-MRSA) infection of pediatric patients in a tertiary care hospital in Riyadh, Saudi Arabia. Int J Pediatr Adolesc Medi. 2016;3(2):71–7.CrossRef
15.
Tarai B, Das P, Kumar D. Recurrent challenges for clinicians: emergence of methicillin-resistant Staphylococcus aureus, vancomycin resistance, and current treatment options. J Lab Phys. 2013;5(2):71.
16.
17.
Agerie NW. Determinants of smallholder rural farm households’ participation in small scale irrigation and its effect on income in North Gondar zone: a cross-sectional approach (evidence from Dembia Woreda). Ethiopia: Mekelle University; 2013.
18.
Nigus D, Lingerew W, Beyene B, Tamiru A, Lemma M, Melaku M. Prevalence of multi drug resistant tuberculosis among presumptive multi drug resistant tuberculosis cases in Amhara National Regional State, Ethiopia. J Mycobac Dis. 2014;4(152):2161–1068.1000152.
19.
Cochran WG. Sampling Techniques. 3rd ed. New York: Wiley; 1977.
20.
Fan J. Local polynomial modelling and its applications: monographs on statistics and applied probability 66. New York: Routledge; 2018.
21.
van der Meulen A. Life tables and survival analysis. The Hague: Statistics Methods Statistics Netherlands; 2012.
22.
Dabrowska DM. Kaplan-Meier estimate on the plane. Ann Stat. 1988;16(4):1475–89.
23.
Brookmeyer R: Median survival time. Wiley StatsRef: Statistics Reference Online 2014.CrossRef
24.
Reid N. Estimating the median survival time. Biometrika. 1981;68(3):601–8.CrossRef
25.
Brueffer C, Vallon-Christersson J, Grabau D, Ehinger A, Häkkinen J, Hegardt C, Malina J, Chen Y, Bendahl P-O, Manjer J. Clinical value of RNA sequencing–based classifiers for prediction of the five conventional breast Cancer biomarkers: a report from the population-based multicenter Sweden Cancerome analysis network—breast initiative. JCO Precis Oncol. 2018;2:1–18.CrossRef
26.
Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika. 1982;69(3):553–66.CrossRef
27.
Xie J, Liu C. Adjusted Kaplan–Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med. 2005;24(20):3089–110.CrossRef
28.
Kleinbaum DG, Klein M. Kaplan-Meier survival curves and the log-rank test. In: Survival analysis. New York: Springer; 2012. p. 55–96.
29.
Collett D. Modelling survival data in medical research. New York: Chapman and Hall/CRC; 2015.
30.
Cox DR. Regression models and life-tables. In: Breakthroughs in statistics. New York: Springer; 1992. p. 527–41.
31.
Gutierrez RG. Parametric frailty and shared frailty survival models. Stata J. 2002;2(1):22–44.CrossRef
32.
Pike M. A method of analysis of a certain class of experiments in carcinogenesis. Biometrics. 1966;22(1):142–61.CrossRef
33.
Bennett S. Analysis of survival data by the proportional odds model. Stat Med. 1983;2(2):273–7.CrossRef
34.
Van den Berg GJ. Duration models: specification, identification and multiple durations. In: Handbook of econometrics, vol. 5. Germany: Elsevier; 2001. p. 3381–460.
35.
Hougaard P. Modelling heterogeneity in survival data. J Appl Probab. 1991;28(3):695–701.CrossRef
36.
Aalen O, Borgan O, Gjessing H. Survival and event history analysis: a process point of view. New York: Springer Science & Business Media; 2008.
37.
Hougaard P. Survival models for heterogeneous populations derived from stable distributions. Biometrika. 1986;73(2):387–96.CrossRef
38.
Caroni C, Crowder M, Kimber A. Proportional hazards models with discrete frailty. Lifetime Data Anal. 2010;16(3):374–84.CrossRef
39.
Duchateau L, Janssen P. The frailty Model. New York: Springer-Verlega; 2008.
40.
Askin OE, Inan D, Buyuklu AH. Parameter Estimation of Shared Frailty Models Based on Particle Swarm Optimization. Int J Stat Probab. 2017;6(1):48–58.
41.
Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19(6):716–23.CrossRef
42.
Munda M, Rotolo F, Legrand C. Parfm: parametric frailty models in R. J Stat Softw. 2012;51(11):1–20.CrossRef
43.
Cox DR, Snell EJ. A general definition of residuals. J R Stat Soc Ser B Methodol. 1968;30(2):248–75.
44.
Miller Jr, R.G. Survival Analysis. Vol. 66. Chichaster: Wily; 2011.
45.
Wienke A. Frailty models in survival analysis. New York: Chapman and Hall/CRC; 2010.
46.
Swain PK, Grover G. Accelerated failure time shared frailty models: application to HIV/AIDS patients on anti-retroviral therapy in Delhi, India. Turkiye Klinikleri J Biostat. 2016;8(1):13–20.CrossRef
47.
Sahu SK, Dey DK, Aslanidou H, Sinha D. A Weibull regression model with gamma frailties for multivariate survival data. Lifetime Data Anal. 1997;3(2):123–37.CrossRef
48.
Ibrahim JG, Chen M-H, Sinha D. Bayesian survival analysis. New York: Springer Science & Business Media; 2001.
49.
Parmar MM, Sachdeva KS, Dewan PK, Rade K, Nair SA, Pant R, Khaparde SD. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007–2011): evidence leading to policy enhancement. PLoS One. 2018;13(4):e0193903.CrossRef
50.
Hamusse SD, Demissie M, Teshome D, Lindtjørn B. Fifteen-year trend in treatment outcomes among patients with pulmonary smear-positive tuberculosis and its determinants in Arsi zone, Central Ethiopia. Glob Health Action. 2014;7(1):25382.CrossRef
51.
Brust JCMGN, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000–2003. Int J Tuberc Lung Dis. 2010;14(4):413–9.PubMedPubMedCentral
52.
Girum T, Tariku Y, Dessu S. Survival status and treatment outcome of multidrug resistant tuberculosis (MDR-TB) among patients treated in treatment initiation centers (TIC) in South Ethiopia: a retrospective cohort study. Ann Med Health Sci Res. 2017;7(5):331–36.
53.
Mitku AA, Dessie ZG, Muluneh EK, Workie DL. Prevalence and associated factors of TB/HIV co-infection among HIV infected patients in Amhara region, Ethiopia. Afr Health Sci. 2016;16(2):588–95.CrossRef
54.
Rabie H, Decloedt EH, Garcia-Prats AJ, Cotton MF, Frigati L, Lallemant M, Hesseling A, Schaaf HS. Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. Expert Opin Pharmacother. 2017;18(6):589–98.CrossRef
55.
Cox HS, McDermid C, Azevedo V, Muller O, Coetzee D, Simpson J, Barnard M, Coetzee G, van Cutsem G, Goemaere E. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS One. 2010;5(11):e13901.CrossRef
56.
Deshmukh RDDD, Sachdeva KS, Sreenivas A, Kumar AMV, Satyanarayana S, et al. Patient and provider reported reasons for lost to follow up in MDRTB treatment: a qualitative study from a drug resistant TB Centre in India. PLoS One. 2015;10(8):1–11.
57.
Kuaban C, Noeske J, Rieder H, Aït-Khaled N, Abena Foe J, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015;19(5):517–24.CrossRef
Metadata
Title
Survival analysis of time to cure on multi-drug resistance tuberculosis patients in Amhara region, Ethiopia
Authors
Yigzaw Alemu Limenih
Demeke Lakew Workie
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2019
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-019-6500-3

Other articles of this Issue 1/2019

BMC Public Health 1/2019 Go to the issue

Research article

Nearly three in every five prisoners experience common mental disorders (CMDs) in Jimma correctional institution; south-West Ethiopia

Research article

Descriptive epidemiology of cholera outbreak in Nigeria, January–November, 2018: implications for the global roadmap strategy

Research article

The impact of diabetes on labour market participation: a systematic review of results and methods

Research article

Impact of the village health center project on contraceptive behaviors in rural Jordan: a quasi-experimental difference-in-differences analysis

Study protocol

Study protocol: a clinical trial for improving mental health screening for Aboriginal and Torres Strait Islander pregnant women and mothers of young children using the Kimberley Mum's Mood Scale

Research article

Prevalence, incidence, and risk factors of primary open-angle glaucoma - a cohort study based on longitudinal data from a German public health insurance